Literature DB >> 12384197

Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the vaccine: Adverse Event Reporting System.

Robert Ball1, Neal Halsey, M Miles Braun, Lawrence H Moulton, Arnold D Gale, Kottil Rammohan, Max Wiznitzer, Richard Johnson, Marcel E Salive.   

Abstract

The Vaccine Adverse Event Reporting System (VAERS), administered by the FDA and CDC, is the U.S. system for surveillance of vaccine adverse events (AE). Acute encephalopathy age <18 months (EO < 18), age > or =18 months (EO > or = 18), encephalitis (EI), and multiple sclerosis (MS) after vaccination have been reported to VAERS, but reports often contain insufficient information to validate diagnoses. Standardized case definitions would enhance the utility of VAERS reports for AE surveillance. We developed practical case definitions for classification of VAERS reports, and three neurologists independently applied the definitions to reports submitted in 1993. Inter-observer agreement was assessed, and non-concordant classifications were reviewed in a follow-up conference call. Reports of EO < 18 (n = 8), EO > or = 18 (n = 20), EI (n = 15), and MS (n = 16) were classified as "definite" in 7% to 30% of the cases, while 26% to 51% of reports were thought to have insufficient information to make a classification. Agreement among reviewers was good to excellent, (kappa: 0.65 to 0.85) except for EO < 18 m for which it was marginal (kappa: 0.37). It is possible to develop reproducible case definitions for acute encephalopathy, encephalitis, and multiple sclerosis using a standardized approach. Application of standardized case definitions to VAERS reports documents the limited information in many reports, specifies data for supplemental collection, and indicates that VAERS reports should be cautiously interpreted. Development and application of case definitions for other adverse events reported after vaccination should enhance the value of vaccine safety databases. Published by Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384197     DOI: 10.1016/s0895-4356(01)00500-5

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  7 in total

Review 1.  Autoimmune encephalitis and its relation to infection.

Authors:  Arun Venkatesan; David R Benavides
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

2.  Automating case definitions using literature-based reasoning.

Authors:  T Botsis; R Ball
Journal:  Appl Clin Inform       Date:  2013-10-30       Impact factor: 2.342

3.  Diagnosis and management of acute encephalitis: A practical approach.

Authors:  Arun Venkatesan; Romergryko G Geocadin
Journal:  Neurol Clin Pract       Date:  2014-06

4.  Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.

Authors:  A Venkatesan; A R Tunkel; K C Bloch; A S Lauring; J Sejvar; A Bitnun; J-P Stahl; A Mailles; M Drebot; C E Rupprecht; J Yoder; J R Cope; M R Wilson; R J Whitley; J Sullivan; J Granerod; C Jones; K Eastwood; K N Ward; D N Durrheim; M V Solbrig; L Guo-Dong; C A Glaser
Journal:  Clin Infect Dis       Date:  2013-07-15       Impact factor: 9.079

5.  Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database.

Authors:  Julie Mouchet; Bernard Bégaud
Journal:  Drug Saf       Date:  2018-08       Impact factor: 5.228

Review 6.  A clinical approach to diagnosis of autoimmune encephalitis.

Authors:  Francesc Graus; Maarten J Titulaer; Ramani Balu; Susanne Benseler; Christian G Bien; Tania Cellucci; Irene Cortese; Russell C Dale; Jeffrey M Gelfand; Michael Geschwind; Carol A Glaser; Jerome Honnorat; Romana Höftberger; Takahiro Iizuka; Sarosh R Irani; Eric Lancaster; Frank Leypoldt; Harald Prüss; Alexander Rae-Grant; Markus Reindl; Myrna R Rosenfeld; Kevin Rostásy; Albert Saiz; Arun Venkatesan; Angela Vincent; Klaus-Peter Wandinger; Patrick Waters; Josep Dalmau
Journal:  Lancet Neurol       Date:  2016-02-20       Impact factor: 44.182

7.  Causality assessment of adverse events following immunization: the problem of multifactorial pathology.

Authors:  Paolo Bellavite
Journal:  F1000Res       Date:  2020-03-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.